Compounded Semaglutide vs. Ozempic: What It Costs in Chattanooga

I hear the same question from patients in this office and typed into Google before they ever call: is compounded semaglutide just a cheap knockoff of Ozempic? I understand why people ask it here in Chattanooga — this city has med spas, telehealth ads, and a real physician practice all using the word “semaglutide,” and nobody’s explaining the difference between them. I’m Dr. Paul Miranda, board-certified, and I built Summit Metabolic Health to answer that question honestly, with the actual numbers, instead of a reason to call.

“Compounded” describes how a medication is prepared, not what it is. A licensed compounding pharmacy takes semaglutide — the same active pharmaceutical ingredient in Novo Nordisk’s Ozempic and Wegovy — and prepares it to an individual prescription, typically at a lower per-mg cost than a fixed-dose brand pen. That’s the entire mechanism. It’s the same regulatory category pharmacies have used for decades to prepare individualized doses of drugs that are otherwise sold in one fixed strength.

“Knockoff” implies a different, lesser substance. That’s not accurate, and it’s also not the actual risk. The real risk in compounded GLP-1s is sourcing — where the active ingredient came from, whether the pharmacy is licensed, and whether a physician is reviewing the dose. I’ve written about how to evaluate that specific question in a Chattanooga physician’s breakdown of compounded semaglutide safety — the short version is that compounding isn’t the risk. An unmonitored source is.

Ozempic and Wegovy are brand-name, fixed-dose pens manufactured by Novo Nordisk, priced at that manufacturer’s list price regardless of which dose you’re actually on. You pay the same price for the pen whether you’re on the lowest starting dose or the highest maintenance dose.

Compounded semaglutide is billed differently — by the milligram, prepared for your specific prescription. You pay for the dose you’re actually on, not a flat price set for the highest strength in the lineup. That’s the entire cost difference, and it’s a billing structure, not a quality claim. Early in treatment, when your dose is low, your medication cost is low. As the dose climbs on a titration schedule to manage tolerance, the cost climbs with it.

That structure only works, though, if the pricing is actually published somewhere you can read it before you call. Most places treat their real number like a trade secret.

Cost only matters next to outcome, so here’s the outcome data behind the medication itself, not the delivery model. In the STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021), patients on semaglutide 2.4mg lost a mean of 14.9% of body weight at 68 weeks, versus 2.4% on placebo.

Mechanistically, semaglutide works by activating the GLP-1 receptor — slowing gastric emptying and amplifying satiety signaling in the brain (Drucker, Cell Metabolism, 2018). Patients describe it as the constant background hum of thinking about food finally going quiet. That mechanism doesn’t change based on who manufactured the vial. The molecule is the molecule.

Read the 14.9% figure carefully, though: it’s a group average from a clinical trial, not a promise about you. And it assumes patients actually reached and stayed on an effective maintenance dose. A program priced and marketed only around its cheapest starting dose, and quiet about what the maintenance dose costs, isn’t pricing the outcome that produced 14.9%. It’s pricing the number that gets you to click.

Compounded GLP-1 pricing nationally has been climbing, and it’s worth understanding why before you commit to any provider’s “starting at” number.

Several of the largest direct-to-consumer telehealth platforms have restricted or exited compounded semaglutide over the past year, pivoting to branded-only offerings with steep introductory promotions. I’ve broken down what that shift actually costs patients without insurance in this Chattanooga pricing guide for semaglutide without insurance — and the pattern repeats across the category. Hims/Hers now runs roughly $448–548/month once the promotional window ends. Ro lands around $498/month on its branded plan. NovoCare’s own direct-to-patient pricing runs $349–499/month depending on dose and insurance status.

The mechanism is consistent: an introductory rate gets you in the door, then the price jumps once you’re already dependent on the medication working. That’s the price cliff. It’s not a hidden fee — it’s a business model built on the assumption that once you’re 12 weeks in and the food noise has quieted down, you won’t shop around before the renewal hits.

None of that is a knock on any patient who’s on one of those plans. It’s a structural fact about how introductory-rate marketing works, and it’s exactly why I publish Summit’s real number instead of a promotional one.

Summit’s active weight-loss membership is $149/month, flat. That covers physician visits, dose adjustments, side-effect management, and lab review — the clinical work, not the drug itself. Medication is billed separately, at pass-through pricing per milligram of compounded semaglutide dispensed, so your cost tracks the dose you’re actually on: roughly $175–200/month all-in at a starting dose, rising to roughly $350–400/month all-in at a typical maintenance dose. I broke down that itemized, milligram-based math in full in this Chattanooga semaglutide pricing guide if you want the line-by-line version.

Here’s the part that separates this from a subscription model: I don’t push patients to the highest dose as fast as the label allows. I titrate slowly, hold the dose every 25 pounds lost to let the body and the habit catch up, and at goal weight, I taper down to the lowest dose that holds the result — sometimes that floor is zero. The price follows the dose. When the dose comes down at maintenance, so does the bill. No cliff, no lock-in contract, no fee that quietly changes shape at month four.

And I’m the one reading the chart. Not a questionnaire routed through software, not a rotating contractor pool — I personally review every chart before a patient starts and at every dose change. That’s a structural difference from a call-center prescriber model, not a marketing line.

Safety in compounded GLP-1s comes down to two questions, and neither of them is “is compounding legal” — it is, under standard pharmacy law.

First: is the compounding pharmacy licensed, and can the provider tell you exactly where the active ingredient is sourced? A provider who can’t answer that in one sentence hasn’t earned your card number. Second: is a physician actually adjusting your dose based on how you’re tolerating it, or is a fixed titration schedule running on autopilot regardless of your side effects? That second question is where a checkbox form and a physician-reviewed chart diverge — how fast you move up the schedule is a clinical judgment call, not something a form field decides for you.

Ask any provider, mine included, these three things before you start: who compounds the medication and are they licensed, who is reviewing your chart and are they a physician, and what happens to the price once you reach maintenance. If a provider can’t answer all three without a sales pitch attached, keep asking.

Compounded semaglutide isn’t a knockoff of Ozempic. It’s the same active molecule, prepared and billed differently — and the safety and the price both come down to who’s managing it, not what it’s called. I’d rather you have the real number and the real answer now than find out both on the phone. For more on how we approach GLP-1 pricing, dosing, and safety, the Summit blog has the rest of what we’ve written.

Ready to start? Apply at summitmetabolichealth.com/apply.